News

Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
Eli Lilly: The Worst May Be Already Over (Earnings Preview)
Eli Lilly stock is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Read the full earnings preview here.
Eli Lilly’s weight loss drug most effective at preventing heart attacks and strokes: What new study means for Mounjaro users
Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...
Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage
Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post reported that Medicare and Medicaid programs are planning to experiment with ...
Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients
Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...
GLP-1 Pill From Eli Lilly Leads to Weight Loss and May Be Available Next Year
In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...